CA2630413C - Process for recovery of iopromide, suitable for pharmaceutical purposes, from mother liquors - Google Patents
Process for recovery of iopromide, suitable for pharmaceutical purposes, from mother liquors Download PDFInfo
- Publication number
- CA2630413C CA2630413C CA2630413A CA2630413A CA2630413C CA 2630413 C CA2630413 C CA 2630413C CA 2630413 A CA2630413 A CA 2630413A CA 2630413 A CA2630413 A CA 2630413A CA 2630413 C CA2630413 C CA 2630413C
- Authority
- CA
- Canada
- Prior art keywords
- iopromide
- isomer
- crystallizate
- dissolved
- process according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and at least three atoms of bromine or iodine, bound to carbon atoms of the same non-condensed six-membered aromatic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
This invention describes a process for recovery of iopromide, suitable for pharmaceutical purposes, by heat treatment of the mother liquors or the secondary crystallizate in a reactor and subsequent crystallization.
Description
Process for Recovery of Iopromide, Suitable for Pharmaceutical Purposes, from Mother Liquors.
The invention relates to a process for recovery of iopromide, suitable for pharmaceutical purposes, by heat treatment of mother liquors or dissolved secondary crystallizate in a reactor and subsequent crystallization.
lopromide, 5-methoxyacetylamino-2,4,6-triiodo-isophthalic acid-[(2,3-dihydroxy-N-methyl-propy1)-(2,3-dihydroxypropyl)]-diamide, (DE 196 41 178 C and EP 0 015 B), is an iodine-containing x-ray contrast medium with the following chemical structure:
I Li 0 N \ OH
/0j .1 OH
lopromid [Iopromide]
The bulky iodine atoms prevent, to a great extent, the free rotation of the bond, identified by 1 in the structural formula, between the aromatic ring and the amide group with the dihydroxypropyl-methylamino group by the presence of the N-methyl group, so that two atropisomers that are thermally quite stable occur. Such atropisomers are described in, i.a., "Recent Advances in Atropisomerism" by M. Oki in the journal "Topics in Stereochemistry," 1983, Volume 14, pages 1-81, and Tetrahedron Letters No.
38, pages 4593-4598, 1966. In the case of one of the atropisomers, the substituted nitrogen atom lies above the ring plane; with other isomers, it lies below the ring plane.
The two atropisomeric compounds (isomer 1 and isomer 2) are different in their physical properties, especially in their solubilities in water and organic solvents.
Only iopromide of a certain composition relative to these atropisomers is allowed as an x-ray contrast medium (40-51% isomer 1 and 49-60% isomer 2).
Iopromide for pharmaceutical purposes is obtained by crystallization from ethanol. In this connection, a mixture that consists of about 48% isomer 1 and about 52%
isomer 2 accumulates regularly. The mother liquor contains the isomer 1 at about 60%
and the isomer 2 at only up to about 40%. For this reason, only a secondary crystallizate with a false composition relative to the atropisomers can be recovered from the mother liquor (contains too much isomer 1).
In the production of iopromide, a final crystallization that consists of alcohol is performed herein. In this connection, a proportion of about 10% of iopromide remains in dissolved form in the mother liquor, which becomes apparent as a loss of yield.
Earlier tests -- to crystallize out additional iopromide from the accumulating mother liquors by secondary crystallization and thus to increase the yield --failed, since the iopromide K2 recovered from the mother liquors is not in accordance with specifications with respect to the atropisomeric ratio. This behavior can be attributed to the fact that certain atropisomers preferably accumulate in the mother liquor.
Object of the Invention:
The production processes for iopromide that are known from the prior art herein exhibit the drawback that a higher loss in yield must be tolerated and no technical process exists that allows iopromide, which is in accordance with specifications with respect to the atropisomeric ratio and thus can be used for pharmaceutical purposes, to be recovered from the mother liquors.
Resolution of the Invention:
The above-described drawbacks could be resolved, surprisingly enough, in that first a K2 is recovered from the iopromide, pure mother liquor, by a suitable secondary crystallization, which then is isomerized in a continuous tubular-flow reactor in accordance with specifications by a suitable heat treatment, without significant decomposition of the substance occurring.
According to one aspect of the invention, there is provided a process for recovery of iopromide, the process comprising:
crystallizing dissolved secondary or subsequent crystallizate from an iopromide mother liquor, after heat treatment of said dissolved secondary or subsequent crystallizate in a tubular flow reactor;
wherein the iopromide contains atropisomeric forms in an amount of 40 to 51%
isomer 1 and 49 to 60% isomer 2.
According to another aspect of the invention, there is provided a process for recovery of iopromide, the process comprising:
crystallizing iopromide from mother liquor, dissolving said iopromide in a solvent, heat treating said dissolved iopromide in a tubular flow reactor, and crystallizing iopromide;
wherein the crystallized iopromide contains atropisomeric forms in an amount of 40 to 51% isomer 1 and 49 to 60% isomer 2.
The invention thus contains a process for recovery of iopromide and iopromide mother liquors, suitable for pharmaceutical purposes, or solutions of the secondary and subsequent crystallizates by heat treatment of the solution, preferably in a tubular-flow reactor at 100-300 C, advantageously at 200-220 C, and then quick cooling to room temperature and crystallization. The heat treatment in a flow reactor is advantageously carried out in aqueous solution at hydrodynamic dwell times of 1 to 60 minutes.
Preferably the atropisomers are dissolved in a solvent. More preferably, the solvent is water. The total yield of iopromide can be increased quite significantly by this process according to the invention, such that the economic efficiency increases. In addition, less halogen-containing waste accumulates.
3a The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
Brief Description of the Drawing:
Fig. 1 illustrates an experimental set-up for heat isomerization of the iopromide secondary crystallizate.
Description of the Process in Detail:
First, a secondary crystallizate is recovered from the iopromide, pure mother liquors, by the ethanolic mother liquors being concentrated by evaporation by the factor = CA 02630413 2008-05-20 =
The invention relates to a process for recovery of iopromide, suitable for pharmaceutical purposes, by heat treatment of mother liquors or dissolved secondary crystallizate in a reactor and subsequent crystallization.
lopromide, 5-methoxyacetylamino-2,4,6-triiodo-isophthalic acid-[(2,3-dihydroxy-N-methyl-propy1)-(2,3-dihydroxypropyl)]-diamide, (DE 196 41 178 C and EP 0 015 B), is an iodine-containing x-ray contrast medium with the following chemical structure:
I Li 0 N \ OH
/0j .1 OH
lopromid [Iopromide]
The bulky iodine atoms prevent, to a great extent, the free rotation of the bond, identified by 1 in the structural formula, between the aromatic ring and the amide group with the dihydroxypropyl-methylamino group by the presence of the N-methyl group, so that two atropisomers that are thermally quite stable occur. Such atropisomers are described in, i.a., "Recent Advances in Atropisomerism" by M. Oki in the journal "Topics in Stereochemistry," 1983, Volume 14, pages 1-81, and Tetrahedron Letters No.
38, pages 4593-4598, 1966. In the case of one of the atropisomers, the substituted nitrogen atom lies above the ring plane; with other isomers, it lies below the ring plane.
The two atropisomeric compounds (isomer 1 and isomer 2) are different in their physical properties, especially in their solubilities in water and organic solvents.
Only iopromide of a certain composition relative to these atropisomers is allowed as an x-ray contrast medium (40-51% isomer 1 and 49-60% isomer 2).
Iopromide for pharmaceutical purposes is obtained by crystallization from ethanol. In this connection, a mixture that consists of about 48% isomer 1 and about 52%
isomer 2 accumulates regularly. The mother liquor contains the isomer 1 at about 60%
and the isomer 2 at only up to about 40%. For this reason, only a secondary crystallizate with a false composition relative to the atropisomers can be recovered from the mother liquor (contains too much isomer 1).
In the production of iopromide, a final crystallization that consists of alcohol is performed herein. In this connection, a proportion of about 10% of iopromide remains in dissolved form in the mother liquor, which becomes apparent as a loss of yield.
Earlier tests -- to crystallize out additional iopromide from the accumulating mother liquors by secondary crystallization and thus to increase the yield --failed, since the iopromide K2 recovered from the mother liquors is not in accordance with specifications with respect to the atropisomeric ratio. This behavior can be attributed to the fact that certain atropisomers preferably accumulate in the mother liquor.
Object of the Invention:
The production processes for iopromide that are known from the prior art herein exhibit the drawback that a higher loss in yield must be tolerated and no technical process exists that allows iopromide, which is in accordance with specifications with respect to the atropisomeric ratio and thus can be used for pharmaceutical purposes, to be recovered from the mother liquors.
Resolution of the Invention:
The above-described drawbacks could be resolved, surprisingly enough, in that first a K2 is recovered from the iopromide, pure mother liquor, by a suitable secondary crystallization, which then is isomerized in a continuous tubular-flow reactor in accordance with specifications by a suitable heat treatment, without significant decomposition of the substance occurring.
According to one aspect of the invention, there is provided a process for recovery of iopromide, the process comprising:
crystallizing dissolved secondary or subsequent crystallizate from an iopromide mother liquor, after heat treatment of said dissolved secondary or subsequent crystallizate in a tubular flow reactor;
wherein the iopromide contains atropisomeric forms in an amount of 40 to 51%
isomer 1 and 49 to 60% isomer 2.
According to another aspect of the invention, there is provided a process for recovery of iopromide, the process comprising:
crystallizing iopromide from mother liquor, dissolving said iopromide in a solvent, heat treating said dissolved iopromide in a tubular flow reactor, and crystallizing iopromide;
wherein the crystallized iopromide contains atropisomeric forms in an amount of 40 to 51% isomer 1 and 49 to 60% isomer 2.
The invention thus contains a process for recovery of iopromide and iopromide mother liquors, suitable for pharmaceutical purposes, or solutions of the secondary and subsequent crystallizates by heat treatment of the solution, preferably in a tubular-flow reactor at 100-300 C, advantageously at 200-220 C, and then quick cooling to room temperature and crystallization. The heat treatment in a flow reactor is advantageously carried out in aqueous solution at hydrodynamic dwell times of 1 to 60 minutes.
Preferably the atropisomers are dissolved in a solvent. More preferably, the solvent is water. The total yield of iopromide can be increased quite significantly by this process according to the invention, such that the economic efficiency increases. In addition, less halogen-containing waste accumulates.
3a The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.
Brief Description of the Drawing:
Fig. 1 illustrates an experimental set-up for heat isomerization of the iopromide secondary crystallizate.
Description of the Process in Detail:
First, a secondary crystallizate is recovered from the iopromide, pure mother liquors, by the ethanolic mother liquors being concentrated by evaporation by the factor = CA 02630413 2008-05-20 =
2-16 and being dissolved in an alcohol at elevated temperature. Examples of suitable alcohols are alkanols such as methanol, ethanol, 1-propanol, 2-propanol, I-butanol, and 2-butanol. Ethanol, 1-propanol and 2-propanol are preferably used, especially preferably 1-propanol, since the crystallization from this solvent takes place especially quickly and completely and thus is economical. To achieve the crystallization, it can be completely inoculated with iopromide. The K2 crystallizate is then isolated, washed and dried according to known methods.
Example 1:
Production of the K2 Crystallizate 12,000 g of iopromide, pure mother liquor (solid content about 6.2%), is concentrated by evaporation in a vacuum to form viscous oil of 892 g. 877 g of this residue is mixed in a suitable reaction vessel at a bath temperature of 65 C
with 439 ml --of 1-propanol while being stirred. After inoculation with 0.73 g of iopromide, it is fully stirred for another 48 hours at a bath temperature of 65 C. The crystal suspension is then cooled to 20 C, stirred for 1 hour at this temperature and suctioned off via a suction filter.
After washing with 4 portions of 110 ml of ethanol, the secondary crystallizate is dried at 40 C in a vacuum-drying oven.
Yield: 363.8 g (about 52% of the experiment) The secondary crystallizate that is obtained from the mother liquor has the following atropisomeric ratio:
HPLC Specification Result Isomer 1 40.0 ¨ 51.0% 62.2 %
Isomer 2 49.0 ¨ 60.0% 37.8%
The recovered secondary crystallizate is then brought into solution, i.e., dissolved in water and heat-isomerized in a pressure-resistant, suitably designed, continuously-operating tube reactor. In this connection, hydrodynamic dwell times of 1 to 60 minutes, preferably 1-30 minutes, especially preferably 1 to 10 minutes, are set at temperatures of between 100 to 300 C, preferably 150 C to 250 C, preferably 180 C to 230 C, especially preferably 200 C to 220 C. In a downstream heat exchanger, the heat-treated iopromide K2 solution is then quickly cooled to room temperature.
Example 2:
Heat-Isomerization of the Iopromide Secondary Crystallizate 280 g of iopromide-K2 from Example I is dissolved in 520 g of water. The solution is then pumped at a volumetric flow rate of 3 ml/minute through a flow pipe that is provided with a pressurization valve of 20 bar at 208-209 C. The flow pipe that is used has an inside diameter of 1.7526 mm and a heated length Of 5.5 m (see Figure 1).
A solution of the isomerized iopromide secondary crystallizate is then purified via ion-exchange columns and crystallized from ethanol.
The yield of the iopromide that is crystallized from ethanol is approximately 80%
of the experiment relative to the secondary crystallizate that is used in the isomerization.
The crystallizate shows a content after HPLC (standard method) of greater than 97.5% relative to the external standard and has the following atropisomeric ratio:
HPLC Specification Result Isomer 1 40.0 ¨ 51.0% 49.4%
Isomer 2 49.0¨ 60.0% 50.6%
Example 1:
Production of the K2 Crystallizate 12,000 g of iopromide, pure mother liquor (solid content about 6.2%), is concentrated by evaporation in a vacuum to form viscous oil of 892 g. 877 g of this residue is mixed in a suitable reaction vessel at a bath temperature of 65 C
with 439 ml --of 1-propanol while being stirred. After inoculation with 0.73 g of iopromide, it is fully stirred for another 48 hours at a bath temperature of 65 C. The crystal suspension is then cooled to 20 C, stirred for 1 hour at this temperature and suctioned off via a suction filter.
After washing with 4 portions of 110 ml of ethanol, the secondary crystallizate is dried at 40 C in a vacuum-drying oven.
Yield: 363.8 g (about 52% of the experiment) The secondary crystallizate that is obtained from the mother liquor has the following atropisomeric ratio:
HPLC Specification Result Isomer 1 40.0 ¨ 51.0% 62.2 %
Isomer 2 49.0 ¨ 60.0% 37.8%
The recovered secondary crystallizate is then brought into solution, i.e., dissolved in water and heat-isomerized in a pressure-resistant, suitably designed, continuously-operating tube reactor. In this connection, hydrodynamic dwell times of 1 to 60 minutes, preferably 1-30 minutes, especially preferably 1 to 10 minutes, are set at temperatures of between 100 to 300 C, preferably 150 C to 250 C, preferably 180 C to 230 C, especially preferably 200 C to 220 C. In a downstream heat exchanger, the heat-treated iopromide K2 solution is then quickly cooled to room temperature.
Example 2:
Heat-Isomerization of the Iopromide Secondary Crystallizate 280 g of iopromide-K2 from Example I is dissolved in 520 g of water. The solution is then pumped at a volumetric flow rate of 3 ml/minute through a flow pipe that is provided with a pressurization valve of 20 bar at 208-209 C. The flow pipe that is used has an inside diameter of 1.7526 mm and a heated length Of 5.5 m (see Figure 1).
A solution of the isomerized iopromide secondary crystallizate is then purified via ion-exchange columns and crystallized from ethanol.
The yield of the iopromide that is crystallized from ethanol is approximately 80%
of the experiment relative to the secondary crystallizate that is used in the isomerization.
The crystallizate shows a content after HPLC (standard method) of greater than 97.5% relative to the external standard and has the following atropisomeric ratio:
HPLC Specification Result Isomer 1 40.0 ¨ 51.0% 49.4%
Isomer 2 49.0¨ 60.0% 50.6%
Claims (8)
1. A process for recovery of iopromide, the process comprising:
crystallizing dissolved secondary or subsequent crystallizate from an iopromide mother liquor, after heat treatment of said dissolved secondary or subsequent crystallizate in a tubular flow reactor;
wherein the iopromide contains atropisomeric forms in an amount of 40 to 51%
isomer 1 and 49 to 60% isomer 2.
crystallizing dissolved secondary or subsequent crystallizate from an iopromide mother liquor, after heat treatment of said dissolved secondary or subsequent crystallizate in a tubular flow reactor;
wherein the iopromide contains atropisomeric forms in an amount of 40 to 51%
isomer 1 and 49 to 60% isomer 2.
2. A process according to claim 1, wherein the iopromide that is contained in the mother liquor or the secondary or subsequent crystallizate has an isomeric ratio that is outside the range of ratios defined in claim 1.
3. A process according to claim 1, wherein the heat treatment in a tubular-flow reactor is carried out at 100 to 300° C.
4. A process according to claim 1, wherein the crystallization is carried out from an alcohol.
5. A process according to claim 1, wherein the iopromide suitable for pharmaceutical purposes is obtained by temperature treatment of atropisomers that are dissolved in a solvent.
6. A process according to claim 5, wherein a hydrodynamic dwell time of the atropisomers that are dissolved in a solvent in the tubular-flow reactor is 1 to 60 minutes.
7. A process according to claim 6, wherein water is used as a solvent.
8. A process for recovery of iopromide, the process comprising:
crystallizing iopromide from mother liquor, dissolving said iopromide in a solvent, heat treating said dissolved iopromide in a tubular flow reactor, and crystallizing iopromide;
wherein the crystallized iopromide contains atropisomeric forms in an amount of 40 to 51% isomer 1 and 49 to 60% isomer 2.
crystallizing iopromide from mother liquor, dissolving said iopromide in a solvent, heat treating said dissolved iopromide in a tubular flow reactor, and crystallizing iopromide;
wherein the crystallized iopromide contains atropisomeric forms in an amount of 40 to 51% isomer 1 and 49 to 60% isomer 2.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE200510059191 DE102005059191B4 (en) | 2005-12-05 | 2005-12-05 | Process for the recovery of pharmaceutically acceptable iopromide from mother liquors |
| DE102005059191.4 | 2005-12-05 | ||
| US74817505P | 2005-12-08 | 2005-12-08 | |
| US60/748,175 | 2005-12-08 | ||
| PCT/EP2006/010943 WO2007065534A1 (en) | 2005-12-05 | 2006-11-10 | Method for recovering iopromide suitable for pharmaceutical purposes from mother liquors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2630413A1 CA2630413A1 (en) | 2007-06-14 |
| CA2630413C true CA2630413C (en) | 2013-06-25 |
Family
ID=37773154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2630413A Expired - Fee Related CA2630413C (en) | 2005-12-05 | 2006-11-10 | Process for recovery of iopromide, suitable for pharmaceutical purposes, from mother liquors |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1960348A1 (en) |
| JP (1) | JP2009518325A (en) |
| KR (1) | KR20080073369A (en) |
| CA (1) | CA2630413C (en) |
| WO (1) | WO2007065534A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100976097B1 (en) * | 2008-12-05 | 2010-08-16 | 주식회사 대웅제약 | Method for selective crystallization of iopromide z isomer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2909439A1 (en) * | 1979-03-08 | 1980-09-18 | Schering Ag | NEW NON-ionic x-ray contrast agents |
| GB9720969D0 (en) * | 1997-10-02 | 1997-12-03 | Nycomed Imaging As | Process |
-
2006
- 2006-11-10 WO PCT/EP2006/010943 patent/WO2007065534A1/en active Application Filing
- 2006-11-10 KR KR1020087016311A patent/KR20080073369A/en not_active Application Discontinuation
- 2006-11-10 EP EP06818545A patent/EP1960348A1/en not_active Withdrawn
- 2006-11-10 JP JP2008543678A patent/JP2009518325A/en active Pending
- 2006-11-10 CA CA2630413A patent/CA2630413C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009518325A (en) | 2009-05-07 |
| WO2007065534A1 (en) | 2007-06-14 |
| EP1960348A1 (en) | 2008-08-27 |
| KR20080073369A (en) | 2008-08-08 |
| CA2630413A1 (en) | 2007-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2730794A1 (en) | Methods and systems for preparing materials for sucralose production | |
| CN111499529B (en) | Synthetic method of ultraviolet absorber UVA Plus | |
| JP2012188437A (en) | Method for producing monopentaerythritol of high purity | |
| RU2019130882A (en) | METHOD FOR PRODUCING CHLORIDE OR BROMIDE 3,7-BIS- (DIMETHYLAMINO) -PHENOTHIAZIN-5-IYA | |
| CN102863505B (en) | Process for synthesizing triamcinolone acetonide acetate | |
| CA2630413C (en) | Process for recovery of iopromide, suitable for pharmaceutical purposes, from mother liquors | |
| US5948940A (en) | Process for iohexol manufacture | |
| US8252922B2 (en) | Method for crystallizing sucralose | |
| US7541494B2 (en) | Process for the manufacture of iohexol | |
| US7723544B2 (en) | Process for recovery of iopromide, suitable for pharmaceutical purposes, from mother liquors | |
| CN108947800B (en) | Synthesis method of (1S) -4, 5-dimethoxy-1- (carbonylaminomethyl) benzocyclobutane | |
| EP0790979B1 (en) | Process for the crystallization from water of (s)-n,n'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzendicarboxamide | |
| CN1102141C (en) | Process for purifying 3.5-dimethyl benzoic acid | |
| CN109836424B (en) | Method for preparing caffeine by methylation of environment-friendly theophylline sodium salt | |
| WO2008003637A2 (en) | Isolation and use of amine salts of mycophenolic acid | |
| CN109456172B (en) | Method for purifying dodecanedioic acid in water phase | |
| CN105440053B (en) | A kind of recovery method of GCLE crystalline mother solutions | |
| CN108147988A (en) | A kind of preparation method of high chiral purity lactam compound | |
| US3875222A (en) | Process for the production of malic acid | |
| CN116199601B (en) | Refining and purifying process of high-content chlorothalonil | |
| WO2009010503A1 (en) | Mycophenolic acid recycling in a method for the preparation of mycophenolate mofetil | |
| CN108083987B (en) | Purification method of ultra-high purity bisphenol A | |
| DE102005059191B4 (en) | Process for the recovery of pharmaceutically acceptable iopromide from mother liquors | |
| WO2014106419A1 (en) | Process for synthesizing 1-methyl-2-oxo-3,6,7-trioxabicyclo[2,2,2]octane | |
| CN104031009B (en) | The manufacture method of optical activity tetrahydrofuran -2- carboxylic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20141110 |